Cardiopulmonary Complications of Ergot-Derivative Dopamine Agonists

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We read with interest the study by Cavallaro et al.¹ that evaluated the usefulness of cabergoline in treating risperidoneinduced hyperprolactinemia. The authors of this small, 8-week study concluded that low-dose cabergoline is a safe and effective treatment for many patients with risperidone-induced hyperprolactinemia. We are concerned, however, about reports linking the ergot-derivative dopamine agonists with cardiopulmonary disease.